This review covers newly published patent applications that describe sigma-2 receptor ligands capable of modulating disease states. The aforementioned documents entered the public domain as PCT patent applications between 2013 and 2018.
In 2017, the sigma-2 receptor was positively identified as TMEM97 (transmembrane protein 97). The resolution of this \'identity crisis\' will facilitate a greater understanding of the pharmacological role of sigma-2 receptor as well as support the identification of novel sigma-2 receptor ligands with potential utility as disease-modifying therapies.